Pain Management Urine Profile (13 Drugs), Urine (PMP‑13)
Use
This test is designed to screen for the presence of up to 13 commonly abused prescription and illicit drugs in urine to support pain management monitoring, compliance, and detection of unauthorized drug use. It includes initial immunoassay screening followed by confirmatory testing via mass spectrometry for any non‐negative results, improving specificity and reducing false positives. Specimen validity markers (e.g., creatinine, specific gravity, pH) help assess sample integrity.
Special Instructions
Not provided.
Limitations
Positive screening results require confirmation by mass spectrometry to verify the presence of detected substances. Urine specimens with invalid integrity markers (e.g., low creatinine, abnormal specific gravity or pH) may compromise results and require recollection. Initial immunoassay may produce false positives for certain compounds due to cross-reactivity; confirmation testing is essential.
Methodology
Immunoassay (Multiplex Protein Panel)
Biomarkers
LOINC Codes
- 19261-7
- 19270-8
- 14316-4
- 18282-4
- 14314-9
- 19295-5
- 58430-0
- 3936-2
- 19550-3
- 19429-0
- 3746-5
- 59673-4
- 19710-3
- 2161-8
- 2965-2
- 2756-5
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Urine
Volume
30 mL
Minimum Volume
Not provided
Container
Urine container
Storage Instructions
Maintain specimen at room temperature. If arrival at lab will extend beyond 7 days, refrigerate.